Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

BACKGROUND: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (...

ver descrição completa

Detalhes bibliográficos
Autor principal: Aapro, MS (author)
Outros Autores: Van Wijk, FH (author), Bolis, G (author), Chevallier, B (author), Van der Burg, ME (author), Oliveira, CF (author)
Formato: article
Idioma:eng
Publicado em: 2008
Assuntos:
Adenocarcinoma
Cisplatina
Doxorubicina
Neoplasias do Endométrio
Texto completo:http://hdl.handle.net/10400.4/126
País:Portugal
Oai:oai:rihuc.huc.min-saude.pt:10400.4/126

Texto Completo

http://hdl.handle.net/10400.4/126

Registos relacionados